Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Treatment Failure: Incorrect dosages or poor-quality compounds may result in diminished weight-loss outcomes or insufficient blood sugar control
Countries with a positive fiscal case should consider launching a long horizon investment programme now
The linkage between PEG and the drug molecule can be either stable or degradable, the latter being commonly used for prodrugs
US$ 26.53
US$ 26.54
US$ 21.97
US$ 24.34
